During the past decade, Institut nuklearnej a molekularnej mediciny conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut nuklearnej a molekularnej mediciny" #1 collaborator was "Astellas Pharma Inc" with 2 trials as a collaborator and "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 2 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Institut nuklearnej a molekularnej mediciny" are "Prostate Cancer" (2 trials), "Cancer of the Prostate" (1 trials) and "Nonmetastatic Castration-Resistant Prostate Cancer" (1 trials). Many other conditions were trialed in "Institut nuklearnej a molekularnej mediciny" in a lesser frequency.

Most popular intervention types in "Institut nuklearnej a molekularnej mediciny" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Enzalutamide" (2 trials), "Abiraterone" (1 trials), "Placebo" (1 trials), "Placebo for Enzalutamide" (1 trials) and "Prednisone" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institut nuklearnej a molekularnej mediciny" are 2 trials for "Male" genders.

Currently, there are NaN active trials in "Institut nuklearnej a molekularnej mediciny". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Institut nuklearnej a molekularnej mediciny, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Institut nuklearnej a molekularnej mediciny, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".